Crossref
In Silico Discovery and ADMET Pharmacokinetic of Novel Pyrimidinic Selenoureas as Selective Breast Carcinoma Cells (MCF-7) Inhibitors
Clinical Research · 2023
DOI: 10.35702/clinres.10016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Research, 2023. Verfasst von Yusuf Isyaku und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Isyaku, Y., Uzairu, A., & Ja'o, A. M. (2023). In Silico Discovery and ADMET Pharmacokinetic of Novel Pyrimidinic Selenoureas as Selective Breast Carcinoma Cells (MCF-7) Inhibitors. Clinical Research. https://doi.org/10.35702/clinres.10016
Vancouver
Isyaku Y, Uzairu A, Ja'o AM. In Silico Discovery and ADMET Pharmacokinetic of Novel Pyrimidinic Selenoureas as Selective Breast Carcinoma Cells (MCF-7) Inhibitors. Clinical Research. 2023. doi:10.35702/clinres.10016
BibTeX
@article{Isyaku2023,
author = {Isyaku, Yusuf and Uzairu, Adamu and Ja'o, Aliyu Muhammad},
title = {In Silico Discovery and ADMET Pharmacokinetic of Novel Pyrimidinic Selenoureas as Selective Breast Carcinoma Cells (MCF-7) Inhibitors},
journal = {Clinical Research},
year = {2023},
doi = {10.35702/clinres.10016}
}
EUVIMED